Feasibility and acceptability of an integrated mind-body intervention for depression: whole-body hyperthermia (WBH) and cognitive behavioral therapy (CBT)

Ashley E. Mason,Anoushka Chowdhary,Wendy Hartogensis,Chelsea J. Siwik,Osnat Lupesko-Persky,Leena S. Pandya,Stefanie Roberts,Claudine Anglo,Patricia J. Moran,J. Craig Nelson,Christopher A. Lowry,Rhonda P. Patrick,Charles L. Raison,Frederick M. Hecht
DOI: https://doi.org/10.1080/02656736.2024.2351459
2024-05-16
International Journal of Hyperthermia
Abstract:Background: There is a pressing need for effective treatments for major depressive disorder (MDD).
oncology,radiology, nuclear medicine & medical imaging
What problem does this paper attempt to address?
The paper aims to explore the feasibility and acceptability of a combined mind-body intervention that integrates Cognitive Behavioral Therapy (CBT) with Whole-Body Hyperthermia (WBH) in the treatment of Major Depressive Disorder (MDD). Specifically, the objectives of the study are: 1. **Assess Feasibility**: Evaluate the feasibility of the combined intervention by observing whether participants can complete the prescribed CBT and WBH sessions. 2. **Assess Acceptability**: Evaluate the acceptability of the treatment plan based on participants' acceptance levels. 3. **Preliminary Efficacy Assessment**: Although the primary focus is on feasibility and acceptability, the study also includes a preliminary assessment of changes in depressive symptoms, particularly measured by changes in the Beck Depression Inventory-II (BDI-II). 4. **Explore Early Treatment Response**: The study also investigates whether emotional changes before and after the first CBT and WBH sessions can predict changes in depressive symptoms throughout the treatment course. The study results show that most participants were able to complete at least 4 WBH sessions, and all participants completed most of the self-reported depression assessments. Additionally, participants' depressive symptoms significantly improved after treatment, with most participants no longer meeting the diagnostic criteria for MDD. However, due to the small sample size and single design, these results need to be further validated in larger-scale controlled clinical trials in the future.